-
Cover Story: Melanoma: three ways around BRAF inhibition Figure 1. Pathways of acquired resistance in melanoma. BRAF inhibitors can activate one of several prosurvival pathways in melanoma. According to two Nature …
Published on 12/9/2010
-
UCLA researchers have shown that mAbs targeting N-cadherin can inhibit prostate cancer growth, metastasis and progression to castration-resistant disease. If Emtx Therapeutics exercises an option to license and develop …
Published on 12/2/2010
-
European researchers have developed an antibody–small molecule combination that could help treat amyloidosis by lowering levels of serum amyloid P component in circulation and solid organs. GlaxoSmithKline has …
Published on 11/18/2010
-
Hydra Biosciences and Catholic University Leuven researchers have found that antagonizing TRPV4 could provide a new mechanism to treat overactive bladder. The biotech expects that blocking the target will generate fewer…
Published on 11/11/2010
-
U.S. and German researchers have developed a nanoconjugate that selectively targets brain cancer and thus could have fewer dose-limiting toxicities than current therapies. Arrogene Nanotechnology has added the findings …
Published on 11/4/2010
-
U.S. and French researchers have shown that DGAT1, an enzyme involved in lipid droplet biogenesis, is a host factor for HCV infection. The findings may point Via Pharmaceuticals to new uses for its DGAT1 inhibitors, …
Published on 10/28/2010
-
DGAT out of the Bag Figure 1. Model of HCV core recruitment to DGAT1-generated lipid droplets. Diacylglycerol O-acyltransferase-1 (DGAT1) and DGAT2 enzymes help to catalyze triglyceride biosynthesis and are essential…
Published on 10/28/2010
-
A team led by the Dana-Farber Cancer Institute and the Structural Genomics Consortium has identified a selective inhibitor of bromodomains—protein domains that bind and recognize histone acetylation—and has shown its …
Published on 10/21/2010
-
Novartis has uncovered three possible molecular causes for brain tumor resistance to inhibitors of Smoothened, which is a key component of the Hedgehog pathway. The pharma has used the discovery to devise combination …
Published on 10/14/2010
-
A consortium led by the Novartis Institute for Tropical Diseases has identified spiroindolones as a potent new class of antimalarials that could safeguard against parasites resistant to first-line treatments. Novartis …
Published on 10/7/2010
-
Memorial Sloan-Kettering and Dana-Farber researchers have shown that inhibiting Hsp90 may provide better blockade of JAK-2 than selective JAK-2 inhibitors. The finding could prompt companies with Hsp90 inhibitors to …
Published on 9/30/2010
-
A Stanford team has boosted the efficacy of Rituxan by combining the anti-CD20 antibody with mAbs against CD47. The combination could elicit fewer side effects than Rituxan plus chemotherapy, the standard care for non-…
Published on 9/23/2010
-
Lund University researchers have shown that IL-1 receptor accessory protein is a cell surface marker that could be used to isolate and kill chronic myelogenous leukemia stem cells. On the basis of these findings, …
Published on 9/16/2010
-
A team at Cold Spring Harbor Laboratory has found that in cancer, inflammation can drive resistance to epithelial growth factor receptor inhibitors such as Tarceva. Alder Biopharmaceuticals may test this hypothesis by …
Published on 9/9/2010
-
Cover story: Inflaming resistance to Tarceva Box 1. Targeting IL-6 in glioblastoma A study published in Genes and Development provides additional evidence for IL-6 as a therapeutic target in epidermal growth factor …
Published on 9/9/2010
-
Cover story: Inflaming resistance to Tarceva Figure 1. Targeting Tarceva resistance. Yao et al. suggest that blocking IL-6 signaling could reduce resistance to epidermal growth factor receptor (EGFR) inhibitors like …
Published on 9/9/2010
-
A Johns Hopkins team has the first in vivo proof of concept that pharmacological inhibition of LRRK2 is neuroprotective in Parkinson's disease. An undisclosed company has optioned the molecules, putting them in …
Published on 9/2/2010
-
UCLA researchers have identified prostatic basal cells as the originators of prostate cancer and have developed a mouse model based on these findings, which could help identify new treatments that attack the root of the…
Published on 8/26/2010
-
Cover Story: The Root of Prostate Cancer Box 1. Targeting the Root of Prostate Cancer. With the new understanding that basal cells could be the source of prostate cancer, a University Paris Descartes group has …
Published on 8/26/2010
-
An NIH-Northeastern team has demonstrated that peripheral inhibition of the cannabinoid CB1 receptor could treat obesity and related metabolic disorders without the safety issues posed by CNS-acting compounds like …
Published on 8/19/2010
-
Dana-Farber and Scripps Florida scientists have identified an alternative mechanism by which PPAR? agonists could exert their antidiabetic effects. The findings provide a rationale for a renewed look at compounds …
Published on 8/12/2010
-
Cover Story: Resolving the PPARgamma paradox Figure 1. A new way to target PPARg. Harvard Medical School researchers suggest that compounds that block phosphorylation of peroxisome proliferation-activated receptor-g…
Published on 8/12/2010
-
Cover Story: Resolving the PPARgamma paradox Table 1. Targeting PPARg. A study by Harvard Medical School researchers found that the peroxisome proliferation-activated receptor-g (PPARG; PPARg) agonists Avandia …
Published on 8/12/2010
-
Cover Story: Arsenic Against the Hedgehog Figure 1. A model for GLI2 trafficking and inhibition by ATO. Stanford University School of Medicine researchers identified arsenic trioxide (ATO) and other arsenic-…
Published on 8/5/2010
-
Stanford researchers have shown that arsenic trioxide, used to treat acute promyelocytic leukemia, can antagonize the hedgehog pathway and inhibit the growth of hedgehog pathway–driven cancers. The findings could open …
Published on 8/5/2010